Julia Robinson is our clinical and science editor.
The Terrence Higgins Trust has expressed doubt over the government’s ability to meet its deadline of making pre-exposure prophylaxis routinely available on the NHS in England from April 2020.
Nearly 40% of acute trusts in England do not offer any non-pharmacological therapies to help manage symptoms such as distress, aggression and agitation in patients with dementia while they are in hospital, The Pharmaceutical Journal can reveal.
While medicines can be an important part of dementia treatment, there are doubts over whether they provide meaningful benefits for patients. As a result, emphasis is being placed on non-pharmacological approaches, some of which have had a transformative impact on the lives of patients with dementia.
Recent blog posts
Our research briefings are concise and informative; they keep readers up to date with the latest developments in science and clinical research — from novel uses for existing drugs, to studies assessing potential new treatments.
In 2018, our most popular research briefings covered new areas of research that have been particularly topical this year — including medical cannabis, new antibiotics and e-cigarettes — as well as areas that have long been of interest to pharmacists, such as pain management and adherence.
Julia Robinson summarises the pertinent themes discussed during The Pharmaceutical Journal’s Twitter chat held on Wednesday 12 December 2018.